Enhanced Microbial Transglutaminase

eMTG (Enhanced Microbial Transglutaminase) is an enzyme that catalyzes the formation of new isopeptide bonds between the primary amine of a drug linker and glutamine residues at position Q295 of IgG-type antibodies to produce site-specifically conjugated antibody-drug conjugates (ADCs).

Site-specific conjugation is increasingly used in drug research, development, and manufacturing to produce ADCs and bioconjugates with defined drug-to-antibody ratios (DAR) since the resulting homogeneity improves safety and efficacy. Transglutaminase (TG)-mediated bioconjugation is a promising means of conjugating drug linkers specifically to the Q295 position of antibodies. However, its use traditionally requires antibody or glycan engineering since the adjacent glycosylation at N297 interferes with the TG reaction. If you’re interested in trying eMTG to make therapeutic ADCs but do not currently have the conjugation setup/expertise, please consider ADC Express™ Service for pre-clinical lead candidate selection.

• Increased efficiency - with one-step bioconjugation for ADCs

• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product

• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates

• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.

One unit will catalyze the formation of 1.0 micromole of hydroxamate per minute from N Z GLN-GLY and hydroxylamine at pH 6.0 at 37°C.